Source-grounded facts extracted from ADAPTIN BIO, INC.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
ADAPTIN BIO, INC. issued 200,000 shares of common stock to certain investors for $5.00 per Share for gross proceeds of $1.0 million.
“On December 22, 2025, Adaptin Bio, Inc. (the “Company”) entered into a subscription agreement (the “Subscription Agreement”) with certain investors and sold 200,000 shares (the “Shares”) of the Company’s common stock (the “Common Stock”) at $5.00 per Share for gross proceeds of $1.0 million in a closing of a private placement offering (the “Offering”).”
ADAPTIN BIO, INC. underwent a change of control involving Unite Acquisition 1 Corp..
“the completion of the Merger (as defined in the Original Report)”
ADAPTIN BIO, INC.: Registrant ceased to be a shell company as a result of the Merger.
“As a result of the Merger, we have ceased to be a shell company.”
ADAPTIN BIO, INC.: Board adopted a new Code of Ethics in connection with the Merger, applying to all directors, officers, and employees.
“In connection with the Merger, the board of directors adopted a new Code of Ethics, which applies to all directors, officers (including our principal executive officer, principal financial officer, principal accounting officer or controller, or persons performing similar functions) and employees.”
ADAPTIN BIO, INC.: Bylaws amended and restated in their entirety effective upon closing of the Merger.
“Prior to the Merger, we amended and restated our bylaws in their entirety, to be effective upon closing of the Merger.”
ADAPTIN BIO, INC.: Amendment and restatement of certificate of incorporation approved by board on February 11, 2025 and by stockholders on the same date, effective upon the Merger (effective 2025-02-11).
“Prior to the Merger, Unite Acquisition’s board of directors approved the amendment and restatement of our certificate of incorporation on February 11, 2025, and stockholders holding 100% of the then outstanding shares of our Common Stock approved the amendment and restatement to our certificate of incorporation on February 11, 2025.”
ADAPTIN BIO, INC. underwent a change of control involving Adaptin Bio, Inc. (Private Adaptin) (closed 2025-02-11).
“As a result of the Merger, we acquired the business of Private Adaptin and will continue its business operations as a public reporting company under the same name, Adaptin Bio, Inc.”
ADAPTIN BIO, INC. completed an acquisition involving Adaptin Bio, Inc. (Private Adaptin) (closed 2025-02-11).
“On February 11, 2025, Unite Acquisition’s wholly-owned subsidiary, Adaptin Acquisition Co., a Delaware corporation formed in the State of Delaware on January 30, 2025 (“Merger Sub”), merged with and into Adaptin Bio, Inc., a privately held Delaware corporation (“Private Adaptin”) formerly known as Centaur Bio Inc.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.